𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Treatment of patients with metastatic renal cell cancer : A RAND Appropriateness Panel

✍ Scribed by Ronald J. Halbert; Robert A. Figlin; Michael B. Atkins; Myriam Bernal; Thomas E. Hutson; Robert G. Uzzo; Ronald M. Bukowski; Khuda Dad Khan; Christopher G. Wood; Robert W. Dubois

Publisher
John Wiley and Sons
Year
2006
Tongue
English
Weight
256 KB
Volume
107
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

A population-based study evaluating the
A population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer
✍ Daniel Y. C. Heng; Kim N Chi; Nevin Murray; Tao Jin; Jorge A Garcia; Ronald M Bu πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 183 KB πŸ‘ 1 views

## Abstract ## BACKGROUND: Sunitinib has replaced interferon (IFN) as a first‐line standard of care in the treatment of metastatic renal cell carcinoma (RCC). This study aimed to determine overall survival and to confirm effectiveness in a population that includes poor prognosis patients. ## METH

A pilot study of thalidomide in patients
A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma
✍ Danai D. Daliani; Christos N. Papandreou; Peter F. Thall; Xuemei Wang; Cherie Pe πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 96 KB πŸ‘ 2 views

## Background: The highly vascular nature of renal cell carcinoma (rcc) suggests that angiogenesis inhibition may be therapeutic for patients with this disease. thalidomide inhibits basic fibroblast growth factor and vascular endothelial growth factor (vegf)-induced angiogenesis. ## Methods: In a